
Pharma News
-
WHO Allocates $1.5 Billion in Aid, Global Primary Health Care Systems Face Major Challenges!
2024-09-24On 23 September 2024, the World Health Organization (WHO) announced a major collaboration with the world's multilateral development banks to build a massive primary health financing platform totaling $1.5 billion.
-
Baobab Fruit Powder Legalized, Introduction of Clostridium butyricum for Infants Raises Health Risk Concerns!
2024-09-24In this dynamic land of Brazil, health and nutrition have always been one of the national concerns.
-
Austria Revises Food Extract Regulations, MTHF Residue Standards Spark Controversy, Potential Health Risks for Consumers?
2024-09-24In the context of the current growing global concern about food safety and consumer health issues, governments are gradually strengthening the regulation of the use of additives and extractants in food production.
-
AstraZeneca’s Breast Cancer New Drug Clinical Trials Fail: Dato-DXd Overall Survival Rate Improvement Falls Short of Expectations, Market Outlook Worrisome!
2024-09-24AstraZeneca announced the results of an impressive clinical trial on September 23, 2024, in the TROPION-Breast01 Phase III trial of its experimental precision drug Dato-DXd, developed with Daiichi Sankyo of Japan, against a type of breast cancer.
-
The uses of 10 povidone iodine solution
2024-09-2310 povidone iodine solution means that this solution contains 10% povidone iodine (equivalent to 1% titratable iodine) and is a disinfectant. What are the main uses of 10 povidone iodine solution?
-
Povidone iodine solution how to use | Detailed explanation
2024-09-23Povidone iodineis a broad-spectrum antibacterial agent. The following is a brief introduction to povidone iodine solution how to use.
-
FDA Approves AstraZeneca’s Nasal Vaccine: New Self-Administration Rules Raise Safety Concerns, Prohibited for Children and Adolescents!
2024-09-23The U.S. Food and Drug Administration (FDA) announced Friday that it has officially approved AstraZeneca's new label nasal spray flu vaccine, allowing people to self-administer it.
-
FDA Grants Emergency Approval for Sanofi’s New Drug Combo: Multiple Myeloma Patients Face New Risks—Is Disease Progression Risk Reduced by 40%?
2024-09-23Sarclisa has previously been approved by the FDA for multiple myeloma cases that require backup treatment after standard treatment options have failed.
-
Sanofi’s Sarclisa Challenges Johnson & Johnson’s Darzalex: FDA Approves New First-Line Treatment, Targeting a $15 Billion Market!
2024-09-23Since its initial approval by the U.S. Food and Drug Administration (FDA) in 2020, Sarclisa, a drug made by Sanofi, has been specifically used to treat patients with multiple myeloma who have previously received other treatments.
-
BMS Layoffs: 79 Employees in New Jersey Face Unemployment, 2,200 Job Cuts Planned by 2025!
2024-09-23According to a Worker Adjustment and Retraining Notice (WARN), the renowned pharmaceutical company announced that it will lay off 79 employees in Lawrenceville, New Jersey.
-
Lonza Launches Innovaform Accelerator
2024-09-23Global CDMO Lonza recently opened a new facility at its Colmar, France site. The new Innovaform Accelerator will serve as a center of excellence to develop and innovate capsule manufacturing and drug delivery solutions for oral and pulmonary drug delivery
-
FDA Shocking Approval of Kisqali: 25% Increased Recurrence Risk for Early Breast Cancer Patients, Treatment Risks Double?
2024-09-20The benefit of invasive disease-free survival (iDFS) compared to receiving endocrine therapy (ET) alone was consistently observed in all patient subgroups 3-6.
-
FDA Grants Emergency Approval! Eli Lilly's IL-13 Inhibitor Ebglyss Poses New Crisis for Atopic Dermatitis Patients, Affecting Those Aged 12 and Older
2024-09-20Eli Lilly recently announced that the U.S. Food and Drug Administration (FDA) has officially approved its IL-13 inhibitor Ebglyss (lebrikizumab).
-
U.S. 301 Tariffs Hit Hard: Chinese Medical Device Industry Faces 50%-100% Tariff Increase, Company Stock Prices Plummet
2024-09-20The Office of the United States Trade Representative has officially announced the final implementation of the 301 tariffs on Chinese goods, which will be implemented in phases on September 27, 2023, January 1, 2025, and January 1, 2026.
-
Povidone iodine solution first aid antiseptic: how does it work?
2024-09-20Povidone iodine solution first aid antiseptic is a type of iodine tincture, used for skin disinfection and sterilization before and after surgery, prevention and treatment of local wound infections, and first aid for minor cuts, abrasions, burns, etc.
-
GlaxoSmithKline Vaccine Combination Trial Fails: Joint Vaccination Shows Mediocre Results, 177,000 Hospitalization Risk Unchanged!
2024-09-19The trial evaluated two of GSK's key vaccines, Shingrix and Arexvy, in adults over 50 years of age, successfully achieving the study's primary goal.
-
$587 Million Valuation Doubts: BioAge Labs’ IPO Hides Crisis in Obesity Drug Market!
2024-09-19BioAge Labs, a biotechnology company focused on the field of obesity treatments, announced on Wednesday that it is seeking a valuation of up to $587 million in its U.S. initial public offering (IPO), according to regulatory filings.
-
Gavi Invests $50 Million to Purchase 500,000 Vaccine Doses, Pandemic Death Toll Exceeds 700, Global Health Emergency Alarm Sounds!
2024-09-19The Global Alliance for Vaccines and Immunization (Gavi) announced on Wednesday that it will procure 500,000 doses of a new smallpox vaccine produced by Bavarian Nordic.
-
$99 Monthly Fee! Hims & Hers Offers Discounts on Wegovy Weight Loss Drug to Specific Industry Patients, Market Shortage Intensifies, Who Will Protect Patient Rights?
2024-09-19Hims & Hers says on its website that it is offering cimarlutide injections for $199 per month for patients on a 12-month plan.
-
Zantac Cancer Controversy Reignites, Jury Fails to Reach Verdict Again, 70,000 Lawsuits Pending!
2024-09-19A man in Illinois claimed through his legal counsel that he had developed prostate cancer after taking a certain drug.
-
Pharmaceutical Industry Overview
The magazine has been officially published in August 2024 and will be distributed at CPHI Korea 2024 and CPHI Milan 2024. It could be permanently available for download online. We sincerely invite you to join us in the publicity, making full use of the influence of the journal to promote your brand & products, expand your corporate influence in the global market.Published in: Aug. 2024
Hot News
-
Top 10 Global CDMO Rankings in 2022
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Forecast of TOP 10 global best-selling drugs in 2021
-
Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Top 30 best-selling oncology drugs in the world in 2020
-
Breaking News! China's First KRAS G12D Inhibitor Approved for Clinical Use
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan